Abstract
The first KRASG12D inhibitor, MRTX113, leads to regression in multiple mouse models of PDAC as a monotherapy. MRTX113 blocks cancer cell proliferation, induces cancer cell death, and promotes immune infiltration and activation. See related article by Kemp et al., p. 298 (6).
©2023 American Association for Cancer Research.
Publication types
-
Editorial
-
Research Support, N.I.H., Extramural
-
Comment
MeSH terms
-
Animals
-
Carcinoma, Pancreatic Ductal* / drug therapy
-
Carcinoma, Pancreatic Ductal* / genetics
-
Carcinoma, Pancreatic Ductal* / metabolism
-
Cell Proliferation
-
Mice
-
Mice, Transgenic
-
Pancreatic Neoplasms* / drug therapy
-
Pancreatic Neoplasms* / genetics
-
Pancreatic Neoplasms* / metabolism